



SIX Swiss Exchange Ltd
SIX Exchange Regulation
Pfingstweidstrasse 110
CH-8005 Zurich

Mailing address:
P.O. Box
CH-8021 Zurich

T +41 58 399 5454
F +41 58 499 5455
www.six-exchange-regulation.com

Exchange Regulation

Contact person:
Marc Enseleit
T +41 58 399 2978
F +41 58 499 2934
marc.enseleit@six-group.com

Zurich, 19 September 2017

Decision of 19 September 2017 in the matter of the delisting of the secondary listed shares of AbbVie Inc, North Chicago, Illinois, USA with a par value of USD 0.01 each

I. Facts

1. On 23 August 2017 the recognized representative of AbbVie Inc, North Chicago, Illinois, USA («Issuer») filed a delisting application with SIX Exchange Regulation.
2. In the application it was requested that all secondary listed shares with a par value of USD 0.01 each of AbbVie Inc, North Chicago, Illinois, USA (ISIN US00287Y1091) be delisted after a continued listing period of three months after publication of the decision of the Regulatory Board.
3. The shares of the Issuer are primary listed on the New York Stock Exchange (NYSE) and secondary listed on SIX Swiss Exchange.
4. The Issuer explains that the delisting of the secondary listed shares on SIX Swiss Exchange is mainly justified with the low trading volume compared to the trading volume on the NYSE. The Issuer points out that between 1 August 2016 and 31 July 2017, the average daily trading volume on SIX Swiss Exchange was 390 shares compared to the average daily trading volume on the NYSE which was approximately 6.56 million. According to the applicant, the actual trading in the shares on SIX Swiss Exchange occurred on 25 trading days only compared to on all trading days on the NYSE. The shares of the issuer will continue to be listed on NYSE. The applicant also states in its application, that there is no limitation for market participants in Switzerland to trade shares that are listed at NYSE. Hence the interests of stock exchange trading and the investors pursuant to art. 58 paragraph 1 (1) Listing Rules (LR) are fully safeguarded.

II. Reason

5. The delisting process is ruled by art. 58 LR and the Directive on the Delisting of Equity Securities, Derivatives and Exchange Traded Products (DD). According to art. 3 paragraph 1 DD, the issuer itself, in principle, decides on the delisting of securities it has issued. The Regulatory Board may decide on the point in time of the delisting announcement as well as on the last trading day. In its decision, it takes into consideration the protection of investors,

fair and orderly trading, the legal environment and the interests of the applicant. In principal, the period between the delisting announcement and the last day of trading may be no less than three and no more than twelve months. However, when setting this period the Regulatory Board will take a variety of criteria into consideration, such as for example the timing, the free float, liquidity, trading volume and other circumstances such as a listing on a stock exchange with equivalent listing and maintenance requirements recognised by the Regulatory Board.

6. In the present case, the Issuer has filed an application in due form and in due time. The period between the delisting announcement and the last trading day according to the DD has been requested to be set to three months, which corresponds to the practice of SIX Exchange Regulation generally applied to the delisting of an Issuer with a secondary listing on SIX Swiss Exchange. Considering the fact that the primary listing on the NYSE is to be retained, SIX Exchange Regulation agrees with the Issuer's application for delisting three months after publication of this decision.

III. Deployment


1. **The delisting of all secondary listed shares with a nominal value of USD 0.01 each of AbbVie Inc, North Chicago, Illinois, USA (ISIN US00287Y1091) has been granted.**
2. **The delisting of the shares takes place on Thursday, 21 December 2017 provided that all publication requirements according to the Rules of SIX Swiss Exchange will be fulfilled in due time. The last trading day on SIX Swiss Exchange will be on Wednesday, 20 December 2017.**
3. **No fees are owed for the processing of the delisting application according to the list of charges of SIX Swiss Exchange.**

Yours sincerely

SIX Swiss Exchange Ltd



Marc Enseleit
Deputy Head Listing
SIX Exchange Regulation



J. Bischof
Jacqueline Bischof
Legal Counsel Listing
SIX Exchange Regulation

Instruction on the right to appeal

The issuer may lodge an appeal against this decision with the Appeals Board of SIX Swiss Exchange within 20 exchange days of the notification of the decision, provided the issuer has an interest worth of protection in having the decision amended (art. 62 paragraph 2 LR).